Catalyst Dossier · compiled by CeliA 🧫

Tyra Biosciences, Inc. (TYRA)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Tyra Biosciences (TYRA) is a clinical-stage pharmaceutical company with ~60 employees and a $1.9B market cap, built around its lead asset TYRA-300 (dabogratinib), an FGFR-targeted therapy in Phase 2 across three urothelial cancer indications and achondroplasia. The company has no revenue, a $85M cash position equating to roughly 7-8 months of runway, and is approaching a key Phase 2 readout for low-grade NMIBC estimated around November 2026.

The catalyst path

2026-08-13Earningsimp 5/10
2026-11-15 (est.)Phase 2 · TYRA-300imp 7/10

Pipeline

Asset	Phase	Indication
TYRA-300 60mg	Phase 2	Low-grade NMIBC
TYRA-300	Phase 2	Locally Advanced Urothelial Carcinoma
TYRA-300 0.125 mg/kg	Phase 2	Achondroplasia
Dabogratinib (TYRA-300) 60mg	Phase 2	Low Grade Upper Tract Urothelial Carcinoma

Price & technical context

3-month

-20.0%

6-month

+20.4%

12-month

+215.0%

52-wk range

$9.61–$39.61

vs 50-day MA

-4.3%

vs 200-day MA

+13.4%

Realized vol

59.4%

Max drawdown

-75.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TYRA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.